Aussies to spearhead eucalyptus genome project
22 July, 2004 by Susan WilliamsonScientists from around the world have agreed to collaborate on sequencing the complete eucalyptus genome, and formed the International Eucalyptus Genome Consortium at a meeting held in Hobart last week.
Proteome Systems boss critical of 'speculative' report
22 July, 2004 by Graeme O'NeillProteome Systems CEO Keith Williams has described as "highly speculative" a media report this morning which suggested his company might be valued only at AUD$100 million when it lists on the ASX this year, rather than the $300 million valuation it had hoped for.
Starpharma scoops up two ARC grants
21 July, 2004 by Graeme O'NeillStarpharma (ASX:SPL) has received two competitive linkage grants, worth a total of AUD$440,000 over the next three years, from the Australian Research Council to further develop pharmaceutical applications of its proprietary dendrimer macromolecules.
Anadis to raise $4.25m in private placement
21 July, 2004 by Renate KrelleMelbourne-based Anadis (ASX:ANX) is making the best of its lofty share price, announcing today that it will issue 10.9 million shares at AUD$0.30, raising $4.25 million.
Early news from Solbec’s SBP002: no toxicity
20 July, 2004 by Graeme O'NeillPerth biotech Solbec Pharmaceuticals (ASX:SPB) is confident of taking its promising cancer drug SBP002 into Phase II clinical trials after a midstream review of data from its current phase 1 trial.
Xenome starts Phase I trial of pain drug
20 July, 2004 by Graeme O'NeillUnlisted Brisbane biotech Xenome has initiated a Phase I clinical trial of its lead candidate for treating neuropathic pain, Xen2174.
Epitan goes shopping: acquires three dermatology products
19 July, 2004 by Melissa TrudingerEpitan (ASX: EPT) has acquired three dermatological products in its push to become a specialty dermatology pharmaceuticals company.
Burrill fund frustrated by lack of local support
19 July, 2004 by Renate KrelleThe Burrill Australia Life Science Fund has raised AUD$150 of its planned $200 million venture capital fund in just over a year -- but more than half of it comes from overseas institutions.
Pest CRC moves to Qld as southern GM bans bite
16 July, 2004 by Graeme O'NeillQueensland's biotechnology industry is beginning to capitalise on southern discomfort over genetically modified (GM) organisms, with the Cooperative Research Centre for Pest Animal Control (CRC-PAC) shifting its research team from Gungahlin, in Canberra, to the Institute of Molecular Biology at the University of Queensland.
Seventh patient implanted with Ventracor artificial heart
15 July, 2004 by Renate KrelleThe seventh patient has been implanted with Ventracor's (ASX:VCR) VentrAssist left ventricular assistance device as part of the company's pilot trial at the Alfred Hospital in Melbourne.
Biting back: QRxPharma to test 20 deadliest snake venoms
14 July, 2004 by Graeme O'NeillIn 1967, Gosford reptile expert Athol Compton suffered a shallow, grazing bite to his thumb while attempting to capture an unfamiliar, large light brown snake with a dark head in Corner Country, in far southwest Queensland.
BioDiem’s antimicrobial joins the field
14 July, 2004 by Graeme O'NeillMelbourne biotechnology company BioDiem Limited (ASX:BDM) has reported promising results from the first field trial of its BDM-I antimicrobial as a poultry feed additive.
Progen begins phase II PI-88 trial in Taiwan
14 July, 2004 by Graeme O'NeillBrisbane oncology drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) today announced it has begun the fourth and largest Phase II clinical trial of its lead anti-cancer drug PI-88 in patients who have undergone surgery for primary liver cancer.
ChemGenex raises $6.2 million
14 July, 2004 by Melissa TrudingerChemGenex Pharmaceuticals (formerly AGT Biosciences; ASX: CXS) has raised AUD$6.2 million through a 15 per cent placement to existing and new shareholders at $0.48 per share, a discount of almost 15 per cent to yesterday's closing price of $0.56.
Phenomix signs collaboration deal with Genentech
13 July, 2004 by Melissa TrudingerCanberra and San Diego-based Phenomix has signed a multi-year collaboration agreement with Genentech to identify and prioritise drug target for immune disorders.
